|
|
 |
|
| Overview |
| The CD44 antibody can be used for the identification or enumeration of CD44+ cells, e.g. cancer stem cells, by flow cytometry or fluorescence microscopy. |
| Details |
Background information
The CD44 antibody (clone DB105) recognizes the CD44 antigen. CD44 is a marker for many types of cancer stem cells (CSC), including breast CSCs that possess higher tumorigenicity and metastatic potential1, colorectal2, pancreatic3, and prostate4,5 CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, CD44 plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth6. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells. |
| Cross-reactivity |
| The CD44 antibody was tested to react with rhesus monkey (Macaca mulatta) cells. |
| Clone | Isotype |
| DB105 | Mouse IgG1 |
| |
| Figure 1 |
| Cells from U937 (CD44+) and 1881 (CD44–) cell lines were combined and fluorescently stained with CD44-FITC, -PE, and -APC and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence. |
 |
 |
 |
|
|
|
|
| Products |
| CD44-FITC, human |
- for 100 tests (1)
Download datasheet
130-095-195
|
| CD44-PE, human |
- for 100 tests (1)
Download datasheet
130-095-180
|
| CD44-APC, human |
- for 100 tests (1)
Download datasheet
130-095-177
|
| (1) One test corresponds to fluorescent labeling of up to 107 cells in a total volume of 100 μL. |
|
| References |
| 1. Al-Hajj, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100: 3983–3988. |
| 2. Dalerba, P. et al. (2007) Proc. Natl. Acad. Sci. USA 104: 10158–10163. |
| 3. Li, C. P. et al. (2007) Cancer Res. 67: 1030–1037. |
| 4. Patrawala, L. et al. (2006) Oncogene 25: 1696–1708. |
| 5. Collins, A. T. et al. (2005) Cancer Res. 65: 10946–10951. |
| 6. Aruffo, A. et al. (1990 Cell 61: 1303–1313. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
